Insider Selling: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Chairman Sells 35,453 Shares of Stock

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE – Get Rating) Chairman Armando Anido sold 35,453 shares of Zynerba Pharmaceuticals stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $0.60, for a total transaction of $21,271.80. Following the sale, the chairman now owns 576,235 shares of the company’s stock, valued at approximately $345,741. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Zynerba Pharmaceuticals Stock Down 4.8 %

NASDAQ ZYNE traded down $0.03 during trading on Wednesday, reaching $0.60. 128,532 shares of the stock traded hands, compared to its average volume of 264,483. The stock’s 50-day moving average price is $0.57 and its 200 day moving average price is $0.84. Zynerba Pharmaceuticals, Inc. has a fifty-two week low of $0.49 and a fifty-two week high of $2.94.

Zynerba Pharmaceuticals (NASDAQ:ZYNE – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. Analysts expect that Zynerba Pharmaceuticals, Inc. will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Zynerba Pharmaceuticals by 6.8% in the first quarter. Vanguard Group Inc. now owns 1,946,590 shares of the company’s stock valued at $3,990,000 after buying an additional 123,731 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Zynerba Pharmaceuticals by 124.3% in the second quarter. Renaissance Technologies LLC now owns 736,600 shares of the company’s stock valued at $840,000 after buying an additional 408,200 shares in the last quarter. Millennium Management LLC bought a new position in Zynerba Pharmaceuticals in the second quarter valued at approximately $346,000. Dimensional Fund Advisors LP lifted its stake in Zynerba Pharmaceuticals by 104.9% in the first quarter. Dimensional Fund Advisors LP now owns 132,385 shares of the company’s stock valued at $271,000 after buying an additional 67,762 shares in the last quarter. Finally, Vident Investment Advisory LLC lifted its stake in Zynerba Pharmaceuticals by 66.1% in the first quarter. Vident Investment Advisory LLC now owns 83,977 shares of the company’s stock valued at $172,000 after buying an additional 33,418 shares in the last quarter. Institutional investors and hedge funds own 23.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ZYNE shares. HC Wainwright cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 1st. StockNews.com upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 19th.

About Zynerba Pharmaceuticals

(Get Rating)

Zynerba Pharmaceuticals, Inc engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery.